Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Transforming the more common type A blood into type O could build up blood supplies and reduce shortages around the globe.
In a recent settlement, the state agreed to expand coverage of HCV treatment—but only to those with advanced liver scarring.
Such a model is greatly needed for research into a hepatitis C vaccine.
There are many factors that can affect our vision, as well as solutions to help us see more clearly.
University of Washington School of Medicine specialist comments on study findings published in JAMA Network Open.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
Researchers analyzed PPIs’ potential effects on nearly 2,400 participants of nine studies of Mavyret.
Advocates at the Global Liver Institute are declaring the liver disease a “hidden epidemic” across the globe.
Chronic inflammation is associated with numerous harms.
Medicare plans vary and can sometimes be difficult to decipher. Does your plan cover hepatitis C treatment?
A study conducted in Australia treated people attending a syringe services program.
A new study finds strong support for the harm reduction strategy among those most likely to use them.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.